Miltefosine for Mucosal Leishmaniasis

Status

Completed

Phases

Phase 1Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00373776

Enrollment

Registered

2006-09-08

Start date

2004-04-30

Completion date

2006-05-31

Last updated

2006-09-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Leishmaniasis

Keywords

mucosal, leishmaniasis, miltefosine

Brief summary

This trial will study miltefosine as a treatment for mucosal leishmaniasis.

Detailed description

Treat bolivian mucosal leishmaniasis with miltefosine.

Interventions

DRUGmiltefosine 2.5 mg/kg/day for 28 days

Study design

Allocation

NON_RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

12 Years to No maximum

Healthy volunteers

Inclusion criteria

* Mucosal leishmaniasis

Exclusion criteria

* Abnormal liver function tests (LFT) * Abnormal kidney function test * Concomitant diseases

Design outcomes

Primary

Measure	Time frame
Efficacy	—

Secondary

Measure	Time frame
toxicity	—

Countries

Bolivia

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026